| 1 |
Cleveland HH, Knapp KS, Cleveland MJ, Deneke E, Bunce SC. Using ecological momentary assessments of negative affect and craving during residential opioid use disorder treatment to predict patients' relapse to substance use. J Subst Use Addict Treat 2023;146:208931. [PMID: 36880896 DOI: 10.1016/j.josat.2022.208931] [Reference Citation Analysis]
|
| 2 |
Leventelis C, Katsouli A, Stavropoulos V, Karasavvidou A, Papadopoulos P, Barmpas PT, Tasoulis S, Veskoukis AS, Tsironi M. The development and validation of the pandemic medication-assisted treatment questionnaire for the assessment of pandemic crises impact on medication management and administration for patients with opioid use disorders. Nordisk Alkohol Nark 2023;40:76-94. [PMID: 36793483 DOI: 10.1177/14550725221135574] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Taubin D, Berger A, Greenwald D, Greenwald H, Burke C, Gongora DS, Wilens T. A systematic review of virtual reality therapies for substance use disorders: Impact on secondary treatment outcomes. Am J Addict 2023;32:13-23. [PMID: 36128667 DOI: 10.1111/ajad.13342] [Reference Citation Analysis]
|
| 4 |
Yates JR. Stress and addiction. Determinants of Addiction 2023. [DOI: 10.1016/b978-0-323-90578-7.00011-6] [Reference Citation Analysis]
|
| 5 |
Mccord E, Van Hale C, Tang Y. Medical treatments for opioid use disorder. Substance Use and Addiction Research 2023. [DOI: 10.1016/b978-0-323-98814-8.00018-4] [Reference Citation Analysis]
|
| 6 |
Mantsch JR. Corticotropin releasing factor and drug seeking in substance use disorders: Preclinical evidence and translational limitations. Addict Neurosci 2022;4:100038. [PMID: 36531188 DOI: 10.1016/j.addicn.2022.100038] [Reference Citation Analysis]
|
| 7 |
Strigo IA, Murphy E, Mitchell JM, Spadoni AD. Learning from addiction: Craving of prescription opioids in chronic pain sufferers. Neurosci Biobehav Rev 2022;142:104904. [PMID: 36202255 DOI: 10.1016/j.neubiorev.2022.104904] [Reference Citation Analysis]
|
| 8 |
Mcreynolds JR, Wolf CP, Starck DM, Schaps R, Krause LA, Hillard CJ, Mantsch JR. Role of mesolimbic cannabinoid receptor 1 in stress-driven increases in cocaine self-administration in male rats.. [DOI: 10.1101/2022.10.28.514315] [Reference Citation Analysis]
|
| 9 |
Gallassi AD, Nakano EY, de Miranda KG, dos Santos JE, da Silva Rodrigues D, de Oliveira FM. The Increased Alcohol and Marijuana Use Associated with the Quality of Life and Psychosocial Aspects: a Study During the Covid-19 Pandemic in a Brazilian University Community. Int J Ment Health Addiction. [DOI: 10.1007/s11469-022-00937-4] [Reference Citation Analysis]
|
| 10 |
Cless MM, Courchesne-krak NS, Bhatt KV, Marienfeld C, Mittal ML. Clinical correlates of craving among patients seeking treatment for substance use disorder.. [DOI: 10.21203/rs.3.rs-1964876/v1] [Reference Citation Analysis]
|
| 11 |
Santo T Jr, Campbell G, Gisev N, Martino-Burke D, Wilson J, Colledge-Frisby S, Clark B, Tran LT, Degenhardt L. Prevalence of mental disorders among people with opioid use disorder: A systematic review and meta-analysis. Drug Alcohol Depend 2022;238:109551. [PMID: 35797876 DOI: 10.1016/j.drugalcdep.2022.109551] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 12 |
Chiang S, Knapp KS, Bai S, Cleveland HH, Harris KS. Examining within- and between-person facets of negative affect and associations with daily craving among young adults in substance use disorder recovery. Addiction Research & Theory. [DOI: 10.1080/16066359.2022.2102611] [Reference Citation Analysis]
|
| 13 |
Brice-tutt AC, Eans SO, Yakovlev D, Aldrich JV, Mclaughlin JP. An analog of [d-Trp]CJ-15,208 exhibits kappa opioid receptor antagonism following oral administration and prevents stress-induced reinstatement of extinguished morphine conditioned place preference. Pharmacology Biochemistry and Behavior 2022. [DOI: 10.1016/j.pbb.2022.173405] [Reference Citation Analysis]
|
| 14 |
Ibañez GE, Sanchez M, Villalba K, Amaro H. Acting with awareness moderates the association between lifetime exposure to interpersonal traumatic events and craving via trauma symptoms: a moderated indirect effects model. BMC Psychiatry 2022;22:287. [PMID: 35459133 DOI: 10.1186/s12888-022-03931-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Burgess-Hull AJ, Panlilio LV, Preston KL, Epstein DH. Trajectories of craving during medication-assisted treatment for opioid-use disorder: Subtyping for early identification of higher risk. Drug Alcohol Depend 2022;233:109362. [PMID: 35217274 DOI: 10.1016/j.drugalcdep.2022.109362] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Bertz JW, Panlilio LV, Stull SW, Smith KE, Reamer D, Holtyn AF, Toegel F, Kowalczyk WJ, Phillips KA, Epstein DH, Silverman K, Preston KL. Being at work improves stress, craving, and mood for people with opioid use disorder: Ecological momentary assessment during a randomized trial of experimental employment in a contingency-management-based therapeutic workplace. Behaviour Research and Therapy 2022. [DOI: 10.1016/j.brat.2022.104071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 17 |
Gottlieb A, Yatsco A, Bakos-block C, Langabeer JR, Champagne-langabeer T. Machine Learning for Predicting Risk of Early Dropout in a Recovery Program for Opioid Use Disorder. Healthcare 2022;10:223. [DOI: 10.3390/healthcare10020223] [Reference Citation Analysis]
|
| 18 |
Marsch LA, Chen CH, Adams SR, Asyyed A, Does MB, Hassanpour S, Hichborn E, Jackson-Morris M, Jacobson NC, Jones HK, Kotz D, Lambert-Harris CA, Li Z, McLeman B, Mishra V, Stanger C, Subramaniam G, Wu W, Campbell CI. The Feasibility and Utility of Harnessing Digital Health to Understand Clinical Trajectories in Medication Treatment for Opioid Use Disorder: D-TECT Study Design and Methodological Considerations. Front Psychiatry 2022;13:871916. [PMID: 35573377 DOI: 10.3389/fpsyt.2022.871916] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 19 |
Polenick CA, Han BH, Meyers SN, Arnold TD, Cotton BP. Associations between relationship quality and treatment-related stress among couples receiving methadone for opioid use disorder. J Subst Abuse Treat 2022;132:108580. [PMID: 34400033 DOI: 10.1016/j.jsat.2021.108580] [Reference Citation Analysis]
|
| 20 |
Parlier-Ahmad AB, Terplan M, Svikis DS, Ellis L, Martin CE. Recovery capital among people receiving treatment for opioid use disorder with buprenorphine. Harm Reduct J 2021;18:103. [PMID: 34645477 DOI: 10.1186/s12954-021-00553-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 21 |
Clark AE, Goodwin SR, Marks RM, Belcher AM, Heinlein E, Bennett ME, Roche DJO. A Narrative Literature Review of the Epidemiology, Etiology, and Treatment of Co-Occurring Panic Disorder and Opioid Use Disorder. J Dual Diagn 2021;17:313-32. [PMID: 34582313 DOI: 10.1080/15504263.2021.1965407] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 22 |
Stull SW, Bertz JW, Panlilio LV, Kowalczyk WJ, Phillips KA, Moran LM, Lin JL, Vahabzadeh M, Finan PH, Preston KL, Epstein DH. I feel good? Anhedonia might not mean "without pleasure" for people treated for opioid use disorder. J Abnorm Psychol 2021;130:537-49. [PMID: 34472889 DOI: 10.1037/abn0000674] [Reference Citation Analysis]
|
| 23 |
Burgess-Hull AJ, Smith KE, Schriefer D, Panlilio LV, Epstein DH, Preston KL. Longitudinal patterns of momentary stress during outpatient opioid agonist treatment: A growth-mixture-model approach to classifying patients. Drug Alcohol Depend 2021;226:108884. [PMID: 34229153 DOI: 10.1016/j.drugalcdep.2021.108884] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 24 |
Dunphy C, Peterson C, Zhang K, Jones CM. Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder? Drug Alcohol Depend 2021;225:108784. [PMID: 34049104 DOI: 10.1016/j.drugalcdep.2021.108784] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 25 |
Xu Y, Towe SL, Causey ST, Meade CS. Using mobile health technologies to test the association of cocaine use with sexual desire and risky sexual behaviors among people with and without HIV who use illicit stimulants. Drug Alcohol Depend 2021;225:108744. [PMID: 34146909 DOI: 10.1016/j.drugalcdep.2021.108744] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 26 |
Marsch LA, Campbell A, Campbell C, Chen CH, Ertin E, Ghitza U, Lambert-Harris C, Hassanpour S, Holtyn AF, Hser YI, Jacobs P, Klausner JD, Lemley S, Kotz D, Meier A, McLeman B, McNeely J, Mishra V, Mooney L, Nunes E, Stafylis C, Stanger C, Saunders E, Subramaniam G, Young S. The application of digital health to the assessment and treatment of substance use disorders: The past, current, and future role of the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat 2020;112S:4-11. [PMID: 32220409 DOI: 10.1016/j.jsat.2020.02.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 27 |
Strain EC, Kampman KM, Weiss RD. Moving Beyond Medications That Act at the μ Receptor in the Treatment of Opioid Use Disorder. JAMA Psychiatry 2021;78:701-2. [PMID: 33851964 DOI: 10.1001/jamapsychiatry.2021.0259] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 28 |
Panlilio LV, Stull SW, Bertz JW, Burgess-Hull AJ, Lanza ST, Curtis BL, Phillips KA, Epstein DH, Preston KL. Beyond abstinence and relapse II: momentary relationships between stress, craving, and lapse within clusters of patients with similar patterns of drug use. Psychopharmacology (Berl) 2021;238:1513-29. [PMID: 33558983 DOI: 10.1007/s00213-021-05782-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 29 |
Bodnar RJ. Endogenous opiates and behavior: 2019. Peptides 2021;141:170547. [PMID: 33831447 DOI: 10.1016/j.peptides.2021.170547] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 30 |
Mattle AG, Aladeen T, Blondell RD, Capote H, Rainka M. Evaluating outcomes of a clinical pharmacist medication management program in a multidisciplinary practice for outpatient buprenorphine treatment of opioid use disorder. J Am Coll Clin Pharm 2021;4:424-434. [DOI: 10.1002/jac5.1405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 31 |
Sükei E, Norbury A, Perez-Rodriguez MM, Olmos PM, Artés A. Predicting Emotional States Using Behavioral Markers Derived From Passively Sensed Data: Data-Driven Machine Learning Approach. JMIR Mhealth Uhealth 2021;9:e24465. [PMID: 33749612 DOI: 10.2196/24465] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 32 |
Rivera D, Dueker D, Amaro H. Examination of referral source and retention among women in residential substance use disorder treatment: a prospective follow-up study. Subst Abuse Treat Prev Policy 2021;16:21. [PMID: 33653374 DOI: 10.1186/s13011-021-00357-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 33 |
Bergeria CL, Strickland JC, Huhn AS, Strain EC, Dunn KE. A preliminary examination of the multiple dimensions of opioid craving. Drug Alcohol Depend 2021;219:108473. [PMID: 33429294 DOI: 10.1016/j.drugalcdep.2020.108473] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 34 |
Jenkins GJ, Cleveland MJ, Knapp KS, Bunce SC, Cleveland HH. Examining the time-varying association of negative affect and covariates with craving during treatment for prescription opioid dependence with two types of mixed models. Addict Behav 2021;113:106674. [PMID: 33049429 DOI: 10.1016/j.addbeh.2020.106674] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 35 |
Maclean RR, Spinola S, Garcia-vassallo G, Sofuoglu M. The Impact of Chronic Pain on Opioid Use Disorder Treatment Outcomes. Curr Addict Rep 2021;8:100-8. [DOI: 10.1007/s40429-020-00352-6] [Reference Citation Analysis]
|
| 36 |
Fuchs-Leitner I, Yazdi K, Gerstgrasser NW, Tholen MG, Graffius ST, Schorb A, Rosenleitner J. Risk of PTSD Due to the COVID-19 Pandemic Among Patients in Opioid Substitution Treatment. Front Psychiatry 2021;12:729460. [PMID: 34658964 DOI: 10.3389/fpsyt.2021.729460] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 37 |
Friesen EL, Kurdyak P. The impact of psychiatric comorbidity on treatment discontinuation among individuals receiving medications for opioid use disorder. Drug Alcohol Depend 2020;216:108244. [PMID: 32861134 DOI: 10.1016/j.drugalcdep.2020.108244] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 38 |
McHugh RK, Nguyen MD, Fitzmaurice GM, Dillon DG. Behavioral strategies to reduce stress reactivity in opioid use disorder: Study design. Health Psychol 2020;39:806-14. [PMID: 32833482 DOI: 10.1037/hea0000862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 39 |
O'Connor AM, Cousins G, Durand L, Barry J, Boland F. Retention of patients in opioid substitution treatment: A systematic review. PLoS One 2020;15:e0232086. [PMID: 32407321 DOI: 10.1371/journal.pone.0232086] [Cited by in Crossref: 67] [Cited by in F6Publishing: 74] [Article Influence: 22.3] [Reference Citation Analysis]
|
| 40 |
Martinotti G, Alessi MC, Di Natale C, Sociali A, Ceci F, Lucidi L, Picutti E, Di Carlo F, Corbo M, Vellante F, Fiori F, Tourjansky G, Catalano G, Carenti ML, Incerti CC, Bartoletti L, Barlati S, Romeo VM, Verrastro V, De Giorgio F, Valchera A, Sepede G, Casella P, Pettorruso M, di Giannantonio M. Psychopathological Burden and Quality of Life in Substance Users During the COVID-19 Lockdown Period in Italy. Front Psychiatry 2020;11:572245. [PMID: 33101086 DOI: 10.3389/fpsyt.2020.572245] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 13.0] [Reference Citation Analysis]
|
